IRIS
MAFFIOLI, PAMELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.315
EU - Europa 3.902
AS - Asia 3.151
AF - Africa 14
SA - Sud America 10
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 12.400
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.229
CN - Cina 3.094
IE - Irlanda 1.171
UA - Ucraina 917
FI - Finlandia 599
DE - Germania 527
SE - Svezia 251
IT - Italia 207
GB - Regno Unito 137
CA - Canada 76
FR - Francia 23
RU - Federazione Russa 22
IN - India 19
IR - Iran 16
NL - Olanda 15
ES - Italia 10
MU - Mauritius 9
MX - Messico 9
TR - Turchia 7
DZ - Algeria 5
NZ - Nuova Zelanda 5
BE - Belgio 4
BR - Brasile 3
CO - Colombia 3
GR - Grecia 3
HU - Ungheria 3
JO - Giordania 3
PE - Perù 3
PK - Pakistan 3
RO - Romania 3
EE - Estonia 2
EU - Europa 2
JP - Giappone 2
PL - Polonia 2
AT - Austria 1
AU - Australia 1
BG - Bulgaria 1
BH - Bahrain 1
CH - Svizzera 1
CY - Cipro 1
DO - Repubblica Dominicana 1
IQ - Iraq 1
KH - Cambogia 1
LV - Lettonia 1
MK - Macedonia 1
RS - Serbia 1
SG - Singapore 1
TH - Thailandia 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 12.400
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.326
Dublin 1.171
Chandler 1.053
Nanjing 999
Nanchang 421
Ashburn 323
Shenyang 296
Hebei 283
Princeton 283
Lawrence 275
Medford 267
Wilmington 253
Changsha 248
Jiaxing 218
Hangzhou 170
Tianjin 144
Boardman 126
Helsinki 116
Beijing 109
Toronto 67
Cambridge 54
Ann Arbor 53
Woodbridge 49
Seattle 44
Fairfield 33
Milan 33
Norwalk 33
Des Moines 23
Jinan 23
Shanghai 22
Kunming 21
Bruino 19
Pavia 19
Genova 17
Zhengzhou 16
Pune 14
Orange 13
Piscataway 13
New York 12
Ningbo 12
Guangzhou 11
Los Angeles 11
Eindhoven 9
West Jordan 8
Fuzhou 7
Redwood City 7
Taizhou 7
Washington 7
Lanzhou 6
Leawood 6
Berlin 5
Changchun 5
Dearborn 5
Houston 5
Moscow 5
Paris 5
Redmond 5
San Francisco 5
Alcobendas 4
Buffalo 4
Cagliari 4
Genoa 4
Halifax 4
Isernia 4
Kochi 4
Rotterdam 4
Shabestar 4
Verona 4
Amman 3
Auckland 3
Bogotá 3
Bologna 3
Carpenedolo 3
Catania 3
Falkenstein 3
Lima 3
Mississauga 3
Novokuznetsk 3
Rome 3
St Petersburg 3
Tappahannock 3
Borås 2
Bruchsal 2
Brussels 2
Budapest 2
Crotone 2
Edmond 2
Falls Church 2
Grandate 2
Haikou 2
Jinhua 2
London 2
Monza 2
Obregon 2
Palermo 2
Parma 2
Perm 2
Philadelphia 2
Phoenix 2
Potomac 2
Totale 8.907
Salva come PNG Salva come JPEG
Nome #
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial 145
A randomized, placebo-controlled study about the effect of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters 121
Diagnostico y Tratamiento de los desordenes lipidicos. Mc Graw Hill Education 2014. 93
Effects of berberis aristata/silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients 77
Differential effect of candesartan and olmesartan on adipose tissue activity biomarkers in type 2 diabetic hypertensive patients 74
A possible way to improve the glycemic control and the beta cell function during three years: the triple therapy. 73
Diarrea in paziente diabetico 73
A multicenter, randomised, single-blind study on the effects of exenatide or glimepiride on insulin resistance. 70
Comparison between exenatide and glimepiride on metabolic control and on insulin resistance in type 2 diabetic patients with metformin therapy 69
Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study 67
Alkaloids in the nature: pharmacological applications in clinical practice of berberine and mate tea. 66
Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis 65
Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients 64
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation. 63
n-3 PUFAs on metalloproteinases, inflammatory and insulin resistance parameters in dyslipidemic patients after euglycemic clamp and oral fat load. 63
Aerobic physical activity in obese subjects compared to anaerobic/aerobic physical activity 62
Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load 62
Effects of sibutramine plus L-carnitine compared to sibutramine on inflammatory parameters in type 2 diabetic patients 61
Vildagliptin added to metformin on β-cell function after an euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetic patients. 61
Different actions of losartan and ramipril on adipose tissue Activity and vascular remodeling biomarkers in hypertensive patients 61
Berberis aristata/silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients 61
A comparison between sitagliptin or glibenclamide in addition to metformin+pioglitazone on glycemic control and beta-cell function: the triple oral therapy 61
Effects of berberine on lipid profile in subjects with low cardiovascular risk 61
Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. 61
Effect of manidipine-rosuvastatin combination on fibrinolysis, inflammation markers and insulin sensitivity in hypertensive hypercholesterolemic patients 61
Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT study 60
Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus 60
Berberis aristata/Silybum marianum fixed combination (Berberol®) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: A randomized, placebo-controlled, clinical trial. 60
Acarbose compared to placebo on insulin resistance biomarkers in a double-blind, placebo-controlled trial 59
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load 59
Olmesartan/amlodipine combination vs olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients 59
Hypoglycemia, its implications in the clinical practice, and possible ways to prevent it. 59
Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin 58
Anti-obesity drugs: a review about their effects and their safety 58
Effetti di un carico lipidico orale sui marcatori di infiammazione e stress endoteliale nei soggetti sani 58
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia during omega-3 polyunsaturated fatty acids therapy 58
Differenti effetti di candesartan e olmesartan sui parametri di attività del tessuto adiposo in pazienti diabetici di tipo 2 ipertesi 58
Prevalence of erectile dysfunction in males affected by type 2 diabetes and the impact of hyperinsulinemia 58
Metformina in bustine rispetto a metformina nella classica formulazione in compresse: primi risultati di uno studio clinico 58
Confronto tra candesartan e olmesartan sui parametri correlati alla sensibilità insulinica nei pazienti ipertesi con diabete mellito di tipo 2 58
Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients 57
Sitagliptin in aggiunta alla precedente terapia ipoglicemizzante sull'insulino-resistenza e il profilo lipidico: uno studio a due anni 57
Adipocytokines levels in obese and non-obese subjects, an observational study 57
Prevalence and associations of erectile dysfunction in a sample of italian males with type 2 diabetes. 57
A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients 56
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients 56
Effetto del telmisartan sui marcatori infiammatori a digiuno e postprandiale nei pazienti diabetici ipertesi 56
Rosiglitazone maleate and glimepiride in fixed combination for the metabolic control of type 2 diabetes 56
Valutazione dell’infiammazione e delle MMPs nei soggetti con e senza diabete durante OGTT 56
Pharmacotherapy for Obesity 56
Matrix metalloproteinase-2 and – 9 levels in obese patients 55
Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients 55
Candesartan effect on inflammation in hypertension 55
Impact of the glyco-metabolic control on erectile dysfunction in patients with type 2 diabetes mellitus 55
Pioglitazone paragonato a glibenclamide sul profilo lipidico e i parametri infiammatori nei pazienti diabetici di tipo 2 in terapia con metformina durante un carico orale di grassi 55
Effetti di un carico lipidico orale sui marcatori di rimodellamento vascolare nei soggetti sani 55
Valutazione dei livelli di metalloproteasi 2 e 9 e dei loro inibitori nei soggetti con dislipidemia combinata 55
Safety and efficacy of albiglutide-results from two trials 55
Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus 55
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia 54
Effects of thiazolidinediones and sulfonylureas in patients with diabetes 54
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia 54
Effetti della combinazione Berberis aristata/Silybum marianum sul profilo lipidico e la secrezione insulinica in pazienti con basso rischio cardiovascolare 54
Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients 54
Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus. 54
A randomized, double blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. 54
Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial 54
Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone 53
Evaluation of candesartan compared to olmesartan on insulin sensitivity-related parameters in type 2 diabetic hypertensive patients 53
Evaluation of candesartan compared to olmesartan on insulin-sensitivity related parameters in type 2 diabetic hypertensive patients 53
Glycemic excursions and variations of some inflammatory indices in patients with end-stage renal disease with and without type 2 diabetes mellitus undergoing two different dialysis techniques 53
Effects of an olmesartan/amlodipine combination compared to olmesartan or amlodipine monotherapies on some insulin resistance parameters in hypertensive patients 53
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin 53
Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria 53
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. 53
Effetti di sitagliptin o metformina associati a pioglitazone in pazienti diabetici scarsamente controllati 53
Effects of sibutramine plus L-carnitine compared to sibutramine or placebo on inflammatory parameters 53
Effetti di una combinazione di un estratto di berberis aristata/silybum marianum sul profilo lipidico e la secrezione insulinica in pazienti dislipidemici 53
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients 52
Current and emerging pharmacotherapies for the management of hypertension, focus on aliskiren 52
Effetti di un anno di trattamento con exenatide paragonato a glibenclamide in pazienti diabetici di tipo 2 52
The effects of different dialysis treatments on glycemic excursions and inflammation in patients with end-stage renal disease with and without type 2 diabetes mellitus 52
Effects of exenatide + metformin combination on some adipocytokines levels: a comparison with metformin monotherapy 52
A systematic reviewandmeta-analysis of randomized controlled trials investigating the effects of supplementationwith Nigella sativa (black seed) on blood pressure 52
Effetti sulla variabilità glicemica e sul compenso glico-metabolico di metformina, pioglitazone e sitagliptin in pazienti affetti da diabete mellito di tipo 2 52
Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study 51
Effect of aliskiren addition to losartan on fibrinolysis in diabetic hypertensive patients: a three-way crossover study. 51
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation 51
Effetti di un anno di trattamento con orlistat+L-carnitina paragonato a orlistat o placebo sui parametri di insulino-resistenza nei pazienti diabetici 51
Prevalenza e fattori di rischio per la disfunzione erettile nei pazienti con diabete mellito di tipo 2 51
L'importanza di rimettere in discussione una diagnosi già fatta 51
Effetti della formulazione idrosolubile di metformina sul compenso glicemico e sulla qualità della vita in pazienti con diabete mellito di tipo 2 51
The effects of canrenone on inflammatory markers in patients with metabolic syndrome. 51
Caso clinico: efficacia e sicurezza di exenatide LAR in un paziente diabetico obeso tipo 2. 51
Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients 51
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study 51
Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes 50
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients 50
Exenatide or glimepiride on insulin resistance in type 2 diabetic patients 50
Comparative effect of amlodipine and amlodipine plus aliskiren on insulin sensitivity and inflammatory parameters in the treatment of hypertension in patients with metabolic syndrome 50
Totale 5.874
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.373
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.373
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201962 0 0 0 0 0 0 0 0 0 0 55 7
2019/20203.744 1.089 1.720 5 172 1 202 21 188 3 300 43 0
2020/20211.754 221 170 39 176 2 217 8 319 46 286 225 45
2021/20221.031 9 4 65 9 4 6 8 58 59 7 175 627
2022/20233.251 358 193 6 221 372 348 2 198 1.370 40 95 48
2023/20241.011 120 196 38 74 122 260 18 120 9 33 21 0
Totale 12.740